Joseph Decker

Dr. Joseph Decker

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2019 in Biomaterials
Verified
Journal Article
Closed access
LCLiam M. Casey
Liam M. Casey
SKSandeep Kakade
Sandeep Kakade
JDJoseph Decker
Joseph Decker
JRJustin A. Rose
Justin A. Rose
KDKyle Deans
Kyle Deans
RPRyan Pearson
Ryan Pearson

1 July 2018 in Molecular Therapy
Verified
Journal Article
Open access
JPJonghyuck Park
Jonghyuck Park
JDJoseph Decker
Joseph Decker
DMDaniel Margul
Daniel Margul
DSDominique R. Smith
Dominique R. Smith
BCBrian J. Cummings
Brian J. Cummings
LSLonnie D Shea
Lonnie D Shea
Trauma to the spinal cord and associated secondary inflammation can lead to permanent loss of sensory and motor function below the injury level, with the resulting environment serving as a barrier that limits regeneration. In this study, we investigate the localized expression of anti-inflammatory cytokines IL-10 and IL-4 via lentiviral transduction in multichannel bridges. Porous multichannel bridges provide physical guidance for axonal outgrowth with the cytokines hypothesized to modulate the neuroinflammatory microenvironment and enhance axonal regeneration. Gene expression analyses indicated that induced IL-10 and IL-4 expression decreased expression of pro-inflammatory genes and increased pro-regenerative genes relative to control. Moreover, these factors led to increased numbers of axons and myelination, with approximately 45% of axons myelinated and the number of oligodendrocyte myelinated axons significantly increased by 3- to 4-fold. Furthermore, the combination of a bridge with IL-10 and IL-4 expression improved locomotor function after injury to an average score of 6 relative to an average score of 3 for injury alone. Collectively, these studies highlight the potential for localized immunomodulation to decrease secondary inflammation and enhance regeneration that may have numerous applications.

1 November 2018 in Journal of Controlled Release
Verified
Journal Article
Closed access
JPJonghyuck Park
Jonghyuck Park
JDJoseph Decker
Joseph Decker
DSDominique R. Smith
Dominique R. Smith
BCBrian J. Cummings
Brian J. Cummings
AAAileen J. Anderson
Aileen J. Anderson
LSLonnie D Shea
Lonnie D Shea

17 September 2013 in Langmuir
Verified
Journal Article
Closed access
JDJoseph Decker
Joseph Decker
CMChelsea M. Magin
Chelsea M. Magin
CLChristopher J. Long
Christopher J. Long
JFJohn A. Finlay
John A. Finlay
MCMaureen E. Callow
Maureen E. Callow
ABAnthony B. Brennan
Anthony B. Brennan

8 August 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
JWJing Wang
Jing Wang
RORamon Ocadiz-Ruiz
Ramon Ocadiz-Ruiz
MHMatthew S. Hall
Matthew S. Hall
GBGrace G. Bushnell
Grace G. Bushnell
SOSophia M. Orbach
Sophia M. Orbach
LSLonnie D Shea
Lonnie D Shea
Biomaterial scaffolds mimicking the environment in metastatic organs can deconstruct complex signals and facilitate the study of cancer progression and metastasis. Here we report that a subcutaneous scaffold implant in mouse models of metastatic breast cancer in female mice recruits lung-tropic circulating tumor cells yet suppresses their growth through potent in situ antitumor immunity. In contrast, the lung, the endogenous metastatic organ for these models, develops lethal metastases in aggressive breast cancer, with less aggressive tumor models developing dormant lungs suppressing tumor growth. Our study reveals multifaceted roles of neutrophils in regulating metastasis. Breast cancer-educated neutrophils infiltrate the scaffold implants and lungs, secreting the same signal to attract lung-tropic circulating tumor cells. Second, antitumor and pro-tumor neutrophils are selectively recruited to the dormant scaffolds and lungs, respectively, responding to distinct groups of chemoattractants to establish activated or suppressive immune environments that direct different fates of cancer cells.

10 August 2017 in Oncotarget
Verified
Journal Article
Open access
PDF file
SRShreyas S. Rao
Shreyas S. Rao
JSJenna Stoehr
Jenna Stoehr
DDDanijela Dokic
Danijela Dokic
LWLei Wan
Lei Wan
JDJoseph Decker
Joseph Decker
JJJacqueline S Jeruss
Jacqueline S Jeruss
Synergistic effect of eribulin and CDK inhibition for the treatment of triple negative breast cancer Synergistic effect of eribulin and CDK inhibition for the treatment of triple negative breast cancer